X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
SRK-015 (apitegromab) is an investigational fully human monoclonal antibody inhibiting myostatin activation by selectively binding the pro- and latent forms of myostatin in the skeletal muscle. It is being evaluated in preclinical studies for the treatment of Obesity.
Lead Product(s): Apitegromab
Therapeutic Area: Nutrition and Weight Loss Product Name: SRK-015
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 23, 2024
Details:
Scholar Rock intends to use the net proceeds from the offering to advance SRK-015 (apitegromab), develop its clinical and preclinical pipeline, as well as for working capital and other general corporate purposes.
Lead Product(s): Apitegromab
Therapeutic Area: Genetic Disease Product Name: SRK-015
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 16, 2023
Details:
Scholar Rock intends to use the net proceeds from the offering to advance SRK-015 (apitegromab), develop its clinical and preclinical pipeline, as well as for working capital and other general corporate purposes.
Lead Product(s): Apitegromab
Therapeutic Area: Genetic Disease Product Name: SRK-015
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities LLC
Deal Size: $85.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 11, 2023
Details:
SRK-439, a novel investigational myostatin inhibitor, which is investigated for the treatmet of obesity. it plans to initiate a Phase 2 proof-of-concept trial with apitegromab in combination with a GLP-1 receptor agonist (GLP-1 RA) in 2024.
Lead Product(s): SRK-439
Therapeutic Area: Nutrition and Weight Loss Product Name: SRK-439
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2023
Details:
SRK-181 is a selective inhibitor of TGFβ1 activation being developed to overcome primary resistance to checkpoint inhibitor therapy, such as anti-PD-(L)1 antibodies, in advanced cancer. TGFβ1 is the predominant TGFβ isoform expressed in many human tumor types.
Lead Product(s): SRK-181
Therapeutic Area: Oncology Product Name: SRK-181
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
Apitegromab is a selective inhibitor of the activation of myostatin and is an investigational product candidate for the treatment of patients with spinal muscular atrophy (SMA).
Lead Product(s): Apitegromab
Therapeutic Area: Genetic Disease Product Name: SRK-015
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 04, 2022
Details:
SRK-181 is a selective inhibitor of TGFβ1 activation being developed to overcome primary resistance to checkpoint inhibitor therapy, such as anti-PD-(L)1 antibodies.
Lead Product(s): SRK-181
Therapeutic Area: Oncology Product Name: SRK-181
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
New data highlight development of its highly selective, context-dependent TGFβ1 antibody that inhibits proTGFβ1 activation selectively in the context of its extracellular matrix presenting partner, latent TGFβ binding protein.
Lead Product(s): Undisclosed
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2022
Details:
Scholar Rock intends to use the net proceeds, to advance its ongoing and future clinical programs (including the development of SRK-015 (apitegromab) in SMA through the anticipated Phase 3 SAPPHIRE topline data readout and SRK-181 in immuno-oncology).
Lead Product(s): Apitegromab
Therapeutic Area: Genetic Disease Product Name: SRK-015
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: J.P. Morgan Securities
Deal Size: $205.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering June 17, 2022
Details:
New data from the Phase 2 TOPAZ trial extension period evaluating patient outcomes after 24-months of treatment, which support sustained and continued improvement with SRK-015 (apitegromab) for non-ambulatory patients with Types 2 and 3 SMA receiving an SMN therapy.
Lead Product(s): Apitegromab
Therapeutic Area: Genetic Disease Product Name: SRK-015
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 17, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
